Urothelial carcinoma, including bladder, ureter, and renal pelvis cancers, is a common malignancy of the urinary system with over 80,000 new cases per year. Traditional diagnostic methods often lack the sensitivity for early detection, leading to delayed treatment and poorer patient outcomes.

Zhongjing Medical Technology offers in vitro diagnostic (IVD) technologies for urological tumors, focusing on early detection and personalized treatment of urothelial cancer. The core technology utilizes next-generation sequencing (NGS) to analyze tumor-related genes in urine samples, providing a non-invasive approach to identify genetic mutations associated with the disease. By combining gene mutation information with clinical guidelines, expert consensus, research literature, and drug clinical trial results, Zhongjing Medical Technology delivers precision treatment recommendations for cancer patients, assisting clinicians in achieving precise tumor treatment.

NGS-based analysis of urine samples for non-invasive detection of tumor-related genes.

Identification of genetic mutations associated with urothelial carcinoma.

Integration of gene mutation data with clinical guidelines and research findings for comprehensive analysis.

Precision treatment recommendations tailored to individual patient profiles.

The primary audience includes clinical specialists and medical institutions focused on urology and oncology, particularly those seeking advanced diagnostic tools for early and accurate detection of urological cancers.